MedTrace Logo

Monitoring Sleep, Wellbeing, and Glucose Metabolism in PGY1s

NCT05695235 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2023-01-25

No results posted yet for this study

Summary

Overnight on-call schedules can impact sleep, wellbeing, and alertness, which can be detrimental on the performance, physical and mental health of residents. Moreover, rotating shift work may have a long-term negative health impact (e.g. increased risk of diabetes). Within the National University Hospital (NUH), two different systems of rotating on-call schedules are implemented. In the night float system, residents work from 8 pm to 8 am for 5 - 7 consecutive nights once every month, compared to the traditional overnight on-call system, where each resident is on call for 4-6 nights per month (7 am - 5 pm, followed by overnight call until 8 am the next morning). The aim of the current study is to track sleep, wellbeing, and glucose metabolism during the different phases of the night float and traditional on-call schedules.

Conditions

  • Sleep
  • Glucose Metabolism Disorders

Interventions

DEVICE

CGM

Wearable continuous glucose monitoring systems (CGMS) provide a minimally invasive means of passively tracking ambulant interstitial fluid glucose levels in real time.

DEVICE

Oura ring

Wearable sleep tracking device

BEHAVIORAL

Cognitive tasks and questionnaires

Participants will be prompted daily to fill out a short set of wellbeing questions and perform a short alertness test on their mobile phones and laptop.

Sponsors & Collaborators

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-01-01
Primary Completion
2023-06-30
Completion
2023-06-30

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05695235 on ClinicalTrials.gov